Is Pfizer (PFE) Overvalued Even After Its Oncology Progress?
Is Pfizer (PFE) Overvalued Even After Its Oncology Progress? Yahoo Finance
Covered in this story
What has happened since
- Pfizer is up 0.4% since this was published, 2 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Pfizer
- Bank of America: $28.3 → $29 by Oct 2027 · Neutral via TIKR.com
- Cantor Fitzgerald: $28.3 → $28 by Oct 2027 · Neutral via TIKR.com
- JPMorgan: $28.3 → $30 by Oct 2027 · Neutral via The Globe and Mail
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pfizer →Dalsna Finance is currently tracking 51 stories mentioning Pfizer, the earliest published 18 Jun 2026.
Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.